Editas Medicine, Inc. (EDIT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.40-3.61%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Editas Medicine, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	6.52M
EPS	—	-0.184
Annual ending 2026-12-31
Revenue	—	25.79M
EPS	—	-0.777
Annual ending 2027-12-31
Revenue	—	19.46M
EPS	—	-0.71

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Fund operations into Q3 2027	The company expects cash to fund operations into Q3 2027.	Improving	cash runway falls short of Q3 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Initiate first-in-human study by end of 2026	Editas aims to start a first-in-human study by end of 2026.	Intact	study initiation delayed beyond 2026-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and the latest 2026-10-08 release. Management is on track to initiate the first-in-human study of EDIT-401 by end of 2026 with early proof-of-concept data expected, and topline data in 2027. Financials show net loss improved from $25.0 million in 2026-Q1 to $18.2 million in 2026-Q2, and revenue increased from $2.8 million to $11.9 million, reflecting progress in development and collaborations. The trajectory is delivering consistent progress toward clinical milestones. Delivery assessment Oct 24, 2026
Stabilize or improve revenue trajectory	A supporting condition in Editas Medicine, Inc.'s published investment case. The stated target is revenue decline less than -10% YoY.	Improving	revenue decline exceeds -10% YoY in FY27	Revenue growth: 232.31% FY2026-Q2; GAAP. Published target: revenue decline less than -10% YoY. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026232.308552 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0c5b0f3e-a5ce-4dc3-95c8-c923818b595e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.71

$-0.95 → $-0.71 · observed estimates

FY2027 revenue$0.02B

$0.01B → $0.02B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.95	$14,710,839	8 / 8
2026-07-25	$-0.95	$14,710,839	8 / 8
2026-07-26	$-0.95	$14,710,839	8 / 8
2026-07-27	$-0.95	$14,710,839	8 / 8
2026-07-28	$-0.94	$14,683,570	8 / 11
2026-07-29	$-0.95	$14,710,839	8 / 8
2026-07-30	$-0.95	$14,710,839	8 / 8
2026-07-31	$-0.95	$14,710,839	8 / 8
2026-08-01	$-0.95	$14,710,839	8 / 8
2026-08-02	$-0.96	$14,801,920	7 / 10
2026-08-03	$-0.96	$14,801,920	7 / 10
2026-08-04	$-0.95	$14,710,839	8 / 8
2026-08-05	$-0.96	$14,801,920	7 / 10
2026-08-06	$-0.96	$14,801,920	7 / 10
2026-08-07	$-0.78	$19,605,633	7 / 7
2026-08-08	$-0.76	$19,340,290	8 / 8
2026-08-09	$-0.76	$19,340,290	8 / 8
2026-08-10	$-0.76	$19,340,290	8 / 8
2026-08-11	$-0.78	$19,605,633	7 / 7
2026-08-12	$-0.78	$19,605,633	7 / 7
2026-08-13	$-0.75	$19,360,380	7 / 10
2026-08-14	$-0.78	$19,605,633	7 / 7
2026-08-15	$-0.78	$19,605,633	7 / 7
2026-08-16	$-0.78	$19,605,633	7 / 7
2026-08-17	$-0.78	$19,605,633	7 / 7
2026-08-18	$-0.78	$19,605,633	7 / 7
2026-08-19	$-0.78	$19,605,633	7 / 7
2026-08-20	$-0.73	$19,412,163	7 / 8
2026-08-21	$-0.73	$19,412,163	8 / 8
2026-08-22	$-0.73	$19,412,163	8 / 8
2026-08-23	$-0.73	$19,412,163	8 / 8
2026-08-24	$-0.73	$19,412,163	8 / 8
2026-08-25	$-0.73	$19,412,163	8 / 8
2026-08-26	$-0.73	$19,409,435	8 / 8
2026-08-27	$-0.73	$19,409,435	8 / 8
2026-08-28	$-0.73	$19,409,435	8 / 8
2026-08-29	$-0.73	$19,409,435	8 / 8
2026-08-30	$-0.73	$19,409,435	8 / 8
2026-08-31	$-0.73	$19,409,435	8 / 8
2026-09-01	$-0.73	$19,409,435	8 / 8
2026-09-02	$-0.73	$19,409,435	8 / 8
2026-09-03	$-0.73	$19,409,435	8 / 8
2026-09-04	$-0.73	$19,409,435	8 / 8
2026-09-05	$-0.73	$19,409,435	8 / 8
2026-09-06	$-0.73	$19,409,435	8 / 8
2026-09-07	$-0.73	$19,409,435	8 / 8
2026-09-08	$-0.73	$19,409,435	8 / 8
2026-09-09	$-0.73	$19,409,435	8 / 8
2026-09-10	$-0.73	$19,409,435	8 / 8
2026-09-11	$-0.73	$19,409,435	8 / 8
2026-09-12	$-0.73	$19,409,435	8 / 8
2026-09-13	$-0.73	$19,409,435	8 / 8
2026-09-14	$-0.73	$19,409,435	8 / 8
2026-09-15	$-0.73	$19,409,435	8 / 8
2026-09-16	$-0.73	$19,409,435	8 / 8
2026-09-17	$-0.73	$19,409,435	8 / 8
2026-09-18	$-0.73	$19,409,435	8 / 8
2026-09-19	$-0.73	$19,409,435	8 / 8
2026-09-20	$-0.73	$19,409,435	8 / 8
2026-09-21	$-0.73	$19,409,435	8 / 8
2026-09-22	$-0.73	$19,409,435	8 / 8
2026-09-23	$-0.73	$19,409,435	8 / 8
2026-09-24	$-0.73	$19,409,435	8 / 8
2026-09-25	$-0.71	$19,458,649	8 / 9
2026-09-26	$-0.71	$19,458,649	8 / 9
2026-09-27	$-0.71	$19,458,649	8 / 9
2026-09-28	$-0.71	$19,458,649	8 / 9
2026-09-29	$-0.71	$19,458,649	8 / 9
2026-09-30	$-0.71	$19,458,649	8 / 9
2026-10-01	$-0.71	$19,458,649	8 / 9
2026-10-02	$-0.71	$19,458,649	8 / 9
2026-10-03	$-0.71	$19,458,649	8 / 9
2026-10-04	$-0.71	$19,458,649	8 / 9
2026-10-05	$-0.71	$19,458,649	8 / 9
2026-10-06	$-0.71	$19,458,649	8 / 9
2026-10-07	$-0.71	$19,458,649	8 / 9
2026-10-08	$-0.71	$19,458,649	8 / 9
2026-10-09	$-0.71	$19,458,649	8 / 9
2026-10-10	$-0.71	$19,458,649	8 / 9
2026-10-11	$-0.71	$19,458,649	8 / 9
2026-10-12	$-0.71	$19,458,649	8 / 9
2026-10-13	$-0.71	$19,458,649	8 / 9
2026-10-14	$-0.71	$19,458,649	8 / 9
2026-10-15	$-0.71	$19,458,649	8 / 9
2026-10-16	$-0.71	$19,458,649	8 / 9
2026-10-17	$-0.71	$19,458,649	8 / 9
2026-10-18	$-0.71	$19,458,649	8 / 9
2026-10-19	$-0.71	$19,458,649	8 / 9
2026-10-20	$-0.71	$19,458,649	8 / 9
2026-10-21	$-0.71	$19,458,649	8 / 9
2026-10-22	$-0.71	$19,458,649	8 / 9
2026-10-23	$-0.71	$19,458,649	8 / 9
2026-10-24	$-0.71	$19,458,649	8 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	5	2
2026-06-01	7	5	2
2026-07-01	7	4	2
2026-08-01	7	4	2
2026-09-01	8	4	2
2026-10-01	9	3	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 3 Hold · 2 Sell / Strong Sell

1 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 8

$6.00New observation · no comparable prior

$0$3.30$6.60

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Fund operations into Q3 2027Direct metric needs a verified mapping
Initiate first-in-human study by end of 2026Direct metric needs a verified mapping
Stabilize or improve revenue trajectoryRevenue growth: 232.31%

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-55.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Editas Medicine, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The thesis is on watch: development milestones are progressing, but recent performance trails its industry cohort and the business remains loss-making.

What's priced into Editas Medicine, Inc.

The valuation evidence points to EDIT being cheap versus peers, while the model shows a modestly negative expectations gap, meaning expectations appear slightly below its modeled level. The pricing signal is marked justified, with low fragility, but confidence is medium and does not remove the risk of weak results or execution setbacks.

What the fundamentals likely do

Near term, the next earnings update carries meaningful risk: guidance cuts or continued weak peer results could reinforce concerns, and the company operates in a high-miss-rate industry. Over the multi-year view, management is on track to begin EDIT-401’s first-in-human study by the end of 2026, with early proof-of-concept data expected and topline data in 2027; the cash runway is expected to extend into the second half of 2028. The latest reported quarter showed a smaller net loss and higher revenue, though recent performance remains below the industry cohort, and litigation was reported on October 8.

What Editas Medicine, Inc. hinges on

The central swing factor is whether EDIT-401 advances into human testing on schedule and later produces credible clinical evidence consistent with the promising preclinical results. The thesis also depends on maintaining the extended cash runway and avoiding guidance cuts; stronger sector results could help the backdrop, while a weakening jobs trend may weigh on healthcare names.